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Abstract
Background: Rhinovirus (RV) associated early wheezing has been recognized as an independent
risk factor for asthma. The risk is more important than that associated with respiratory syncytial
virus (RSV) disease. No comparative data are available on the immune responses of these diseases.
Objective: To compare T-helper1 (Th1), Th2 and T-regulatory (Treg) cell type cytokine responses
between RV and RSV induced early wheezing.
Methods: Systemic Th1-type (interferon [IFN] -gamma, interleukin [IL] -2, IL-12), Th2-type (IL-4,
IL-5, IL-13) and Treg-type (IL-10) cytokine responses were studied from acute and convalescence
phase serum samples of sole RV (n = 23) and RSV affected hospitalized wheezing children (n = 27).
The pre-defined inclusion criteria were age of 3-35 months and first or second wheezing episode.
Analysis was adjusted for baseline differences. Asymptomatic children with comparable
demographics (n = 11) served as controls for RV-group.
Results: RV-group was older and had more atopic characteristics than RSV-group. At acute phase,
RV-group had higher (fold change) IL-13 (39-fold), IL-12 (7.5-fold), IFN-gamma (6.0-fold) and IL-5
(2.8-fold) concentrations than RSV-group and higher IFN-gamma (27-fold), IL-2 (8.9-fold), IL-5 (5.6-
fold) and IL-10 (2.6-fold) than the controls. 2-3 weeks later, RV-group had higher IFN-gamma
(>100-fold), IL-13 (33-fold) and IL-10 (6.5-fold) concentrations than RSV-group and higher IFN-
gamma (15-fold) and IL-2 (9.4-fold) than the controls. IL-10 levels were higher in acute phase
compared to convalescence phase in both infections (p < 0.05 for all).
Conclusion: Our results support a hypothesis that RV is likely to trigger wheezing mainly in
children with a predisposition. IL-10 may have important regulatory function in acute viral wheeze.
Background
Rhinovirus (RV) is the principal pathogen responsible for
the common cold. It is also the most common virus being
associated with asthma attacks in children (up to 60% of
cases) [1,2]. In wheezy children less than 2 years old at
emergency room and hospital settings, RV is also a com-
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mon agent (up to 41-47%; depends on the risk factors of
asthma) only second to respiratory syncytial virus (RSV,
up to 68% of cases) [3,4]. Studies how viral etiology of
early wheezing may contribute to later development of
asthma have focused almost exclusively on RSV, but
recent studies suggest that RV is equal [5], or more impor-
tant viral risk factor than RSV [6-8].
Rhinoviruses belong to the Picornaviridae  family, small
non-enveloped viruses containing a single-stranded RNA
genome. At least 101 different RV serotypes and over 150
different RV strains have been identified thus far, estab-
lishing RVs as the most diverse group of Picornaviridae
[9,10]. Based on receptor binding properties, RVs are
divided into two classes: the major group binding to intra-
cellular adhesion molecule-1 and the minor group bind-
ing to the very low density lipoprotein receptors. After
viral uptake, RVs trigger cytokine and chemokine
responses upon infection that may lead to airway illness.
Many questions remain unanswered regarding the key
inflammatory mediators involved in early wheezing epi-
sodes associated with RV infection. Despite many in vitro
studies, the number of in vivo studies is very limited and
focussed almost exclusively on adult subjects [11-17].
Cytokine gene polymorphism studies are increasingly
reported in wheezing children [18-21], but there are no
studies comparing cytokine responses in RV and RSV
affected young wheezing children. The available compar-
ative data among young children with wheezing is limited
to atopic characteristics, which have been more pro-
nounced in RV than RSV affected children [5,22], and
thereby, as many studies in adults and one in children,
suggest possible role for cytokines involved in T cell differ-
entiation [11-17]. The aim of our observational study was
to compare systemic T-helper1 (Th1), Th2 and T-regulatory
(Treg) cell type cytokine responses between children with
RV and RSV induced early wheezing. We hypothesised
that RV affected young wheezing children have different T
cell cytokine profile compared to RSV affected children.
Methods
Subjects
The study is a substudy of the VINKU study which took
place in the Department of Pediatrics of Turku University
Hospital (9/2000-5/2002). The original aim was to study
the efficacy of oral prednisolone treatment in hospitalized
wheezing children in relation to viral etiology, i.e. a half
of the patients were randomized to receive oral predniso-
lon for 3 days and the other half placebo in a double blind
design. The methods have been described earlier [7,23].
The present study included all children of the VINKU
study who were 3 to 35 months old, had their first or sec-
ond wheezing episode, had sole RV or RSV infection and
had either acute or convalescent phase serum available
(Fig. 1). In addition, we included asymptomatic control
children who participated to VINKU2 study in the same
institution (10/2008-5/2009). They had not had respira-
tory symptoms within 2 weeks, had never wheezed and
had no chronic illnesses other than possible atopy. All
recruited control children were included to this analysis.
The study protocols were approved by the Ethics Commit-
tee of the Turku University Hospital and informed con-
sent was obtained from the guardian before commencing
the study.
Definitions
Atopy was defied as positive IgE antibodies (>0.35 kU/L)
for any of the common allergens as previously defined
[7,23]. Perennial aeroallergen sensitivity was defined as
sensitization (specific IgE >0.35 kU/L) to dog, cat or Der-
matophagoides pteronyssinus.
Outcome measures
Pre-defined primary and secondary endpoints were clini-
cal as previously reported [23]. Here, we report the com-
parison of serum cytokine levels between sole RV or sole
RSV (14 other respiratory viruses were ruled out) affected
corticosteroid naive wheezing children less than 3 years of
age as exploratory endpoints.
Sample collection and analysis
Laboratory data were collected as previously described
[4,7,23,24]. Serum samples were collected on admission
before randomization to prednisolone or placebo and 2-
3 weeks after discharge. Initially, all available serum sam-
ples (75% of eligible) were used according to pre-defined
study criteria. The convalescent phase serum samples were
analyzed from patients randomized to the placebo group
but not from patients randomized to the prednisolone
group.
Serum cytokine analyses were done according to manu-
facturer's instruction by Human Cytokine LINCO plex Kit
(Millipore Corporation, Billerica, MA). Sensitivity of the
kit was as follows (number of samples below detection
level of all analysed): interferon (IFN) -gamma 0.29 pg/
mL (19/50), interleukin (IL) -2 0.16 pg/mL (18/50), IL-4
0.13 pg/mL (10/50), IL-5 0.01 pg/mL (5/50), IL-10 0.15
pg/mL (0/50), IL-12 0.11 pg/mL (23/50) and IL-13 0.48
pg/mL (24/50). The serum samples were coded, randomly
allocated for two batches and laboratory personnel did
not know the viral etiology of the cases.
Virus culture was done for adenovirus, influenza A and B
viruses, parainfluenza virus (PIV) types 1-3, RSV, entero-
viruses, RV and human metapneumovirus (hMPV) [4,24].
Viral antigens were detected for adenovirus, influenza A
and B viruses, PIV 1-3 and RSV. Levels of IgG antibodies
specific for adenovirus, enteroviruses, influenza A and BRespiratory Research 2009, 10:85 http://respiratory-research.com/content/10/1/85
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viruses, parainfluenza virus types 1/3, RSV were analysed
in paired serum samples, in addition to IgM antibodies
for enteroviruses. PCR was used for the detection of
entero- and RV, RSV, coronaviruses (229E, OC43, NL63
and HKU1), hMPV, human bocavirus, influenza A and B
viruses, adenovirus and PIV 1-4. All rhino-enterovirus
PCR positive samples could not be typed by hybridiza-
tion. Twelve such samples, which were available for
sequence analysis, all turned out to be RVs. On the basis
of this finding, 7 non-typable rhino-enteroviruses were
classified as RV. No viral diagnostics were done for the
controls.
Statistics
No statistical power calculation was done for the cytokine
analyses. The normality of data distribution was tested
using the Kolmogorov-Smirnov test. The t-test, Mann
Whitney U test, Chi square test and Spearman's rank cor-
relation were used when appropriate. The cytokine data
were analysed using regression analysis (generalized lin-
ear model with binomial distribution and log-link). The
backward stepwise multivariate analysis of the differences
in cytokine levels between RV and RSV infection was
adjusted to age, presence of atopy, days of preceding
cough, blood eosinophil count and presence of acute oti-
tis media (i.e. the baseline differences). Only significant
adjustments, i.e. P < 0.05, were kept in the model. The
cytokine data is presented as a fold-difference between RV
and RSV affected children. The statistical analyses were
carried out using SAS/STAT(r) software, Version 9.1.3 SP4
of the SAS System for Windows, SAS Institute Inc., Cary,
NC, USA.
Results
Characteristics of study children
During the study period, 661 children were hospitalized
for acute wheezing. Of these, 293 were enrolled in the
VINKU-study (Fig. 1). Of the 293 children, 67 children
fulfilled study criteria, but in 17 cases (11 RV and 6 RSV
positive) serum samples were not available. The 50 chil-
dren included were 3 to 34 months old, had their first or
second wheezing episode, had confirmed sole RV or sole
RSV infection (14 other respiratory viruses were ruled out)
and were corticosteroid naive at study entry. Twenty-three
children were affected by RV and 27 by RSV. Of the 23 RV
positive cases, 19 [83%] were positive by PCR and 4
[17%] by culture, and of the 27 RSV cases, 26 [96%] were
positive by culture, 26 [96%] by antigen detection, 23
[85%] by PCR and 18 [67%] by serology. The demograph-
ics of age (p > 0.1), sex (p > 0.5), atopy (p > 0.3) and
blood eosinophil count (p > 0.6) did not differ between
the eligible children with sera available (n = 50) com-
Study flow chart Figure 1
Study flow chart.
Eligible for VINKU-study (n=661), 
i.e. hospitalization for acute wheezing and 
age <16 years
Not randomised (n=368)
- Had already participated in the 
study (n=87)
- <3 months old (n=79)
- Lost during study breaks (n=55)
- Systemic corticosteroid treatment 
within 4 weeks (n=48)
- Ready for discharge, respiratory  
symptom score <4 (n=24)
- Refusing (n=27)
- Chronic disease (n=17)
- Difficult communication due to 
language (n=12)
- Severe disease necessitating ICU-
treatment (n=11)
- Guardian not present (n=3)
- Varicella contact in a previously  
intact child (n=2)
- Study physician not notified (n=2)
- Social reasons (n=1)
Enrolled (n=293),
i.e. age >3 months and <16 years
Excluded from 
analysis (n=243):
-A g e  > 3 years (n=65)
- Of the rest, >1 previous
wheezing episode (n=50)
- Of the rest, no viral findings or
other than RV or RSV (n=62)
- Of the rest, mixed infection (n=49)
- Sera not available (n=17)
Accepted for analysis (n=50),
i.e. age 3-35 months, 1st or 2nd 
wheezing episode, sole RV or sole RSV 
infection and corticosteroid naïve
Excluded from 2-3 week 
follow-up analysis (n=31):
- Randomly received prednisolone
after acute phase samples (n=30)
- Of the rest, no sera available (n=1) Follow-up analysis 
2-3 weeks later (n=19),
i.e. randomly received placeboRespiratory Research 2009, 10:85 http://respiratory-research.com/content/10/1/85
Page 4 of 10
(page number not for citation purposes)
pared to those without (n = 17) nor in the subgroups of
RV (n = 34) and RSV (n = 33) positive children (respec-
tively, p > 0.1 and p > 0.3 for all comparisons within virus
groups).
The children positive for RV were slightly older and had
more pronounced atopic/airway inflammatory character-
istics, i.e. levels of allergic sensitization to foods, blood
eosinophils, and exhaled nitric oxide, than those positive
for RSV (Table 1). The longer duration of preceding respi-
ratory symptoms, acute otitis media and use of antibiotics
were more common in the RSV-group than in the RV-
group. No other differences were found in the baseline
characteristics.
Eleven children without respiratory symptoms served as
asymptomatic controls for the RV-group. The demograph-
ics of this control group (mean age 1.0 year [sd 9 months];
5/11 [45%] male; 6/11 [55%] atopic; and median blood
eosinophil count 0.26 × 109/L [interquartile range 0.11,
0.54]) did not differ from the RV-group (respectively, p >
0.1, p > 0.4, p > 0.5 and p > 0.3).
Cytokine levels at acute phase
The RV affected children had higher IL-13, IL-12, IFN-
gamma and IL-5 concentrations in serum than those
affected by RSV at acute phase in univariate models (n =
50, Tables 2 and 3). All these differences remained rela-
tively stable in multivariate models which showed that
the RV-group had 39-fold higher IL-13 (p < 0.0001), 7.5-
fold higher IL-12 (p < 0.0001), 6.0-fold higher IFN-
gamma (p = 0.0005) and 2.8-fold higher IL-5 (p = 0.021)
concentrations in serum than the RSV group. When com-
pared to the asymptomatic control group, the RV-group
had 27-fold higher IFN-gamma (p < 0.0001), 8.9-fold
higher IL-2 (p = 0.0007), 5.6-fold higher IL-5 (p = 0.0018)
and 2.6-fold higher IL-10 (p = 0.0098) serum concentra-
tions at acute phase (n = 34, Tables 2 and 3).
Cytokine levels at convalescence phase
Two to three weeks after discharge (n = 19), the RV
affected children had higher IFN-gamma, IL-13, IL-12, IL-
2, IL-10, IL-12 and IL-2 concentrations in serum than the
RSV affected children in univariate models (Tables 4 and
5). In multivariate models, the RV-group had >100-fold
Table 1: Patient characteristics in rhinovirus and respiratory syncytial virus affected children.
Rhinovirus
(n = 23)
RSV
(n = 27)
P
Age, years 1.4 (0.59) 0.78 (0.61) 0.0012
Male, No. 15 (65%) 16 (59%) 0.67
Atopic, No. 10 (44%) 1 (4%) 0.0009
Food sensitization, No 9 (39%) 1 (4%) 0.0034
Perennial aeroallergen, No. 1 (4%) 0 (0%) 0.47
1st episode, No. 17 (74%) 25 (93%) 0.12
2nd episode, No. 6 (26%) 2 (7%) 0.12
Parental asthma, No. 2 (9%) 6 (22%) 0.26
Parental allergy, No. 13 (57%) 16 (59%) 0.85
Parental smoking, No. 11 (48%) 14 (52%) 0.78
Previous symptoms
Cough, days 2 (1, 3) 4 (3, 5) 0.0072
Wheezing, days 1 (1, 1) 2 (2, 3) 0.053
On entry to the study
RSS, points (0, none to 12, severe) 6.7 (1.4) 6.5 (1.1) 0.45
O2-saturation, % 96 (2.3) 96 (2.5) 0.75
Acute otitis media, No. 11 (48%) 21 (78%) 0.028
Blood eosinophils, × 109/L 0.4 (0.2, 0.6) 0.0 (0.0, 0.1) <0.0001
Blood eosinophils >0.1 × 109/L 20 (87%) 3/26 (12%) <0.0001
Exhaled nitric oxide, ppb1 7.5 (7.0, 12) 5.1 (3.9, 6.5) 0.020
Medication
Salbutamol at ER before entry, mg/kg 0.23 (0.18) 0.19 (0.17) 0.46
Antibiotic treatment, No. 15 (65%) 21 (78%) 0.013
RSV, respiratory syncytial virus; RSS, respiratory symptom score; ER, emergency room.
Values are means (SD), No. (%), or medians (interquartile range).
Continuous data were analysed by t-test except Mann Whitney U test was used for blood eosinophil and exhaled nitric oxide levels. Categoric data 
were analysed by Chi square test.
1rhinovirus group, n = 11, RSV-group, n = 17.Respiratory Research 2009, 10:85 http://respiratory-research.com/content/10/1/85
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higher IFN-gamma (p = 0.0090), 33-fold higher IL-13 (p
< 0.0001) and 6.5-fold higher IL-10 (p < 0.0001) concen-
trations in serum than the RSV-group. The differences in
IL-12 and IL-2 did not persist after adjustments for the
baseline differences. When compared to the asympto-
matic control group, the RV-group had 15-fold higher
IFN-gamma (p = 0.010) and 9.4-fold higher IL-2 (p =
0.0048) serum concentrations in the convalescence phase
(n = 20, Tables 2 and 4).
Cytokine levels: acute vs. convalescence
Nineteen corticosteroid naive wheezing children had
both acute and convalescent samples available. Serum IL-
10 levels were higher in acute phase compared to conva-
lescence phase both in RV (p = 0.039) and RSV infections
Table 2: Serum cytokine levels in rhinovirus and respiratory syncytial virus associated acute wheezing and in the asymptomatic age 
and atopy matched control group for rhinovirus group.
Cytokine Rhinovirus associated acute 
wheezing
Respiratory syncytial virus associated 
acute wheezing
Asymptomatic age and atopy matched 
control group for rhinovirus group
nm e d i a n
(interquartile 
range)
nm e d i a n
(interquartile 
range)
nm e d i a n
(interquartile range)
Th1-type
IFN-gamma 23 12 (9.3, 58) 27 0.00 (0.00, 3.6) 11 0.00 (0.00, 0.00)
IL-2 23 7.87 (2.0, 14) 27 0.00 (0.00, 1.1) 11 0.00 (0.00, 0.82)
IL-12 23 6.5 (0.00, 16) 27 0.00 (0.00, 1.5) 11 0.00 (0.00, 0.00)
Th2-type
IL-4 23 120 (52, 190) 27 17 (0.00, 130) 11 63 (6.5, 460)
IL-5 23 7.4 (2.6, 17) 27 0.50 (0.12, 3.0) 11 1.8 (0.00, 3.8)
IL-13 23 53 (17, 77) 27 0.00 (0.00, 0.86) 11 26 (14, 34)
Treg-type
IL-10 23 43 (28, 74) 26 83 (39, 140) 11 25 (14, 34)
CI, confidence interval; Th, T-helper cell; IFN, interferon; IL, interleukin; Treg, T-regulatory cell.
The unit for all cytokine levels is pg/mL.
Table 3: Difference in cytokine levels when rhinovirus associated acute wheezing is compared to respiratory syncytial virus associated 
acute wheezing and to asymptomatic age and atopy matched control group.
Cytokine RV-group compared to RSV-group RV-group compared to control group
Univariate Multivariate
n fold difference
(95% CI)1
P fold difference
(95% CI)
P adjustments n fold difference
(95% CI)
P
Th1-type
IFN-gamma 50 6.0 (2.1, 18) 0.0005 6.0 (2.1, 18) 0.0005 - 34 27 (7.6, 88) <0.0001
IL-2 50 0.51 (0.13, 2.0) 0.30 0.51 (0.13, 2.0) 0.30 - 34 8.9 (2.9, 26) 0.0007
IL-12 50 11 (3.9, 29) <0.0001 7.5 (2.6, 21) <0.0001 age 34 1.1 (0.16, 5.3) 0.92
Th2-type
IL-4 50 0.90 (0.32, 2.5) 0.84 0.90 (0.32, 2.5) 0.84 - 34 1.0 (0.39, 2.4) 0.98
IL-5 50 2.8 (1.1, 7.0) 0.021 2.8 (1.1, 7.0) 0.021 - 34 5.6 (2.1, 14) 0.0018
IL-13 50 39 (14, 110) <0.0001 39 (14, 110) <0.0001 - 34 0.40 (0.14, 1.0) 0.061
Treg-type
IL-10 49 0.59 (0.33, 1.1) 0.066 0.72 (0.40, 1.3) 0.27 atopy 34 2.6 (1.3, 4.9) 0.0098
RV, rhinovirus; RSV, respiratory syncytial virus; CI, confidence interval; Th, T-helper cell; IFN, interferon; IL, interleukin; Treg, T-regulatory cell.
The data were analysed using regression analysis. In multivariate analysis, adjustments to age, presence of atopy, days of preceding cough, blood 
eosinophil count and presence of acute otitis media (i.e. the baseline differences) were used in a backward stepwise model. Only significant 
adjustments (P < 0.05) were kept in the model.
1i.e. how many folds higher cytokine level is in the RV-group than in the RSV-group or in the control group.Respiratory Research 2009, 10:85 http://respiratory-research.com/content/10/1/85
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(p = 0.0005, Table 5). At acute phase, IL-10 levels corre-
lated strongly and positively with other cytokines in RV
affected children and only with IFN-gamma in RSV
affected children (Table 6). Overall, IL-10 did not corre-
late with age (r = 0.04, p = 0.76).
Next, we compared differences between acute and conva-
lescence phases between RV and RSV infections. Such dif-
ference were found in IL-4 (p = 0.037) and IL-5 (p =
0.046) levels (Table 5). The levels of these cytokines non-
signifantly decreased in RV-group whereas they non-sig-
nificantly increased in RSV-group.
Analysis of bias
Since 17 eligible children did not have sera available, we
tested if it could bias the results. The missing values in RSV
cases were corrected as upper 95% confidence interval val-
ues and the missing values in RV cases were corrected as
lower 95% confidence interval values of corresponding
cytokines, and the difference in cytokine levels in all eligi-
ble children during acute wheezing was analysed. In this
extreme supplementary analysis, the RV-group had 16-
fold higher IL-13 (p < 0.0001), 4.8-fold higher IL-12 (p =
0.0015), and 2.4-fold higher IFN-gamma (p = 0.098)
serum concentrations than RSV-group suggesting that the
direction of the difference of these cytokines is true (oth-
erwise data not shown).
Discussion
Cytokine dysregulation, Th1/Th2  imbalance, plays an
important role in the development of asthma and allergic
diseases. At birth and later in early life, blood cytokine
profile indicates whether PBMC response is skewed
toward a Th2-phenotype (production of IL-4, IL-5 and IL-
13) and away from Th1-phenotype (production of IFN-
gamma). The relative nature of this Th1/Th2 imbalance,
especially IFN-response early in life, has been linked to
antiviral activity and the subsequent development of aller-
gic disease and/or asthma [25].
The principal Th1-cytokine, IFN-gamma, is likely to be
most important cytokine responsible for cell mediated
immunity [25]. It is primarily produced by T-helper lym-
phocytes but is also derived from cytotoxic T cells and NK
cells. IFN-gamma production belongs to nonspecific
defense mechanims, which have direct immunoregula-
tory and antiviral actions, although its capability to
inhibit viral replication is modest. IFN-gamma also inhib-
its allergic responses through its capacity to inhibit IL-4
mediated effects but may also contribute to airway hyper-
responsiveness especially in non-atopic subjects [26]. Pre-
vious in vitro and in vivo studies in adults have shown that
IFN-gamma is highly and dose-dependently inducible by
RV in leukocyte, T cell, or airway epithelial cell cultures
and that blood CD4+ IFN-gamma response is associated
with lower RV loads and less severe symptoms suggesting
Table 4: Difference in cytokine levels in corticosteroid naive children 2-3 weeks after hospitalization for wheezing when rhinovirus 
associated acute wheezing is compared to respiratory syncytial virus associated acute wheezing wheezing and to asymptomatic age 
and atopy matched control group.
Cytokine RV-group compared to RSV-group RV-group compared to control group
Univariate Multivariate
n fold difference
(95% CI)1
P fold difference
(95% CI)
P adjustments n fold difference
(95% CI)
P
Th1-type
IFN-gamma 19 49 (37, 170) 0.0003 120 (6.5, 45000) 0.0090 atopy, eos 20 15 (1.4, 210) 0.010
IL-2 19 8.7 (2.2, 36) 0.0012 1.2 (0.16, 6.3) 0.84 atopy, age, eos 20 9.4 (1.7, 56) 0.0048
IL-12 19 17 (2.4, 110) 0.0014 0.72 (0.047, 14) 0.80 eos 20 1.4 (0.07, 39) 0.80
Th2-type
IL-4 19 0.81 (0.13, 5.2) 0.80 0.61 (0.11, 4.0) 0.56 age, atopy 20 1.0 (0.21, 5.4) 0.98
IL-5 19 1.6 (0.37, 6.8) 0.51 1.6 (0.37, 6.8) 0.51 - 20 2.5 (0.82, 8.2) 0.086
IL-13 19 33 (5.5, 190) <0.0001 33 (5.5, 190) <0.0001 - 20 0.40 (0.11, 1.6) 0.16
Treg-type
IL-10 19 7.7 (2.7, 22) <0.0001 6.5 (2.7, 16) <0.0001 otitis 20 2.6 (1.3, 4.9) 0.11
RV, rhinovirus; RSV, respiratory syncytial virus; CI, confidence interval; Th, T-helper cell; IFN, interferon; eos, blood eosinophil count; IL, 
interleukin; Treg, T-regulatory cell.
The data were analysed using regression analysis. In multivariate analysis, adjustments to age, presence of atopy, days of preceding cough, blood 
eosinophil count and presence of acute otitis media (i.e. the baseline differences) were used in a backward stepwise model. Only significant 
adjustments (P < 0.05) were kept in the model.
1i.e. how many folds higher cytokine level is in the RV-group than in the RSV-group or in the control group.Respiratory Research 2009, 10:85 http://respiratory-research.com/content/10/1/85
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Table 5: Differences in serum cytokine levels in acute and convalescence phases of rhinovirus and respiratory syncytial virus associated 
early wheezing episodes in corticosteroid naive children.
Cytokine Rhinovirus RSV Comparison 
of 
differences
n Acute Convalesce
nce
Difference P n Acute Convalesce
nce
Difference PP
Th1-type
IFN-gamma 9 32 (11, 60) 10 (1.1, 49) -2.3 
(-9.8, 8.6)
0.28 10 0.00 
(0.00, 2.7)
0.00 
(0.00, 0.00)
0.00 
(-2.7, 0.00)
0.33 0.90
IL-2 9 9.99 
(2.3, 13)
4.5 (0.83, 20) -2.3 
(-6.9, 2.6)
0.59 10 0.28 
(0.00, 1.7)
0.70 
(0.00, 2.8)
0.00 
(-0.53, 0.28)
0.51 0.44
IL-12 9 13 (0.30, 16) 3.5 (0.00, 16) -0.30 
(-1.4, 3.5)
0.86 10 0.00 
(0.00, 0.41)
0.00 
(0.00, 2.2)
0.00 
(-0.24, 0.00)
0.83 0.54
Th2-type
IL-4 9 190 
(120, 360)
120 
(34, 280)
-28 (-68, 9.5) 0.16 10 16 (0.00, 65) 43 (6.5, 150) 12 (0.00, 55) 0.34 0.037
IL-5 9 14 (7.4, 28) 3.5 (2.0, 14) -12 
(-14, -1.3)
0.16 10 0.41 
(0.08, 1.0)
0.60 
(0.20, 0.88)
0.13 
(-0.15, 0.68)
0.60 0.046
IL-13 9 59 (25, 81) 52 (13, 70) -7.4 (-12, 43) 0.93 10 0.00 
(0.00, 3.8)
0.00 
(0.00, 3.8)
0.00 
(0.00, 0.00)
0.86 0.59
Treg-type
IL-10 9 75 (52, 120) 32 (11, 57) -44 
(-64, -22)
0.039 10 54 (39, 129) 9.1 (4.1, 14) -50 
(-121, -25)
0.0005 0.66
CI, confidence interval; Th, T-helper cell; IFN, interferon; IL, interleukin; Treg, T-regulatory cell.
Values are medians (interquartile range). Data were analysed by Mann Whitney U test.
The unit for all cytokine levels is pg/mL.
Table 6: Correlation between serum IL-10 and other cytokine levels in corticosteroid naive children with acute wheezing.
Cytokine Rhinovirus Respiratory syncytial virus
n acute n convalescence n acute n convalescence
Th1-type
IFN-gamma 23 r = 0.57 9 r = 0.63 26 r = 0.43 10 r = 0.52
P = 0.0047 P = 0.069 P = 0.029 P = 0.12
IL-2 23 r = 0.50 9 r = 0.63 26 r = -0.27 10 r = 0.34
P = 0.016 P = 0.069 P = 0.19 P = 0.34
IL-12 23 r = 0.54 9 r = 0.43 26 r = -0.027 10 r = 0.66
P = 0.0074 P = 0.24 P = 0.90 P = 0.040
Th2-type
IL-4 23 r = 0.44 9 r = 0.58 26 r = 0.084 10 r = 0.42
P = 0.035 P = 0.10 P = 0.68 P = 0.23
IL-5 23 r = 0.53 9 r = 0.33 26 r = -0.097 10 r = 0.0061
P = 0.0096 P = 0.39 P = 0.64 P = 0.99
IL-13 23 r = 0.50 9 r = 0.50 26 r = 0.11 10 r = 0.55
P = 0.014 P = 0.17 P = 0.58 P = 0.10
CI, confidence interval; Th, T-helper cell; IFN, interferon; IL, interleukin.
Data were analysed by Spearman's rank correlation.Respiratory Research 2009, 10:85 http://respiratory-research.com/content/10/1/85
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protective role for IFN-gamma [11,15,17]. Our study fur-
ther suggests an important role for the IFN-gamma
response in RV associated early wheezing. The results
from the comparison between RV-group and the control
group argue against the suggestion that the high IFN-
gamma levels in RV affected children were due to predis-
position. Previous findings in murine models and our
findings also support the link between IL-12 and IFN-
gamma in virus infection, i.e. the former induces the latter
[27]. However, the role of IL-2 and IL-12 appears to be less
pronounced in RV infections as shown by us here and by
others previously [11,15]. IFN-gamma response was low
in RSV affected children as expected [27,28].
Th1/Th2 cytokine ratio seems to determine the course of
clinical illness, i.e. those with lower ratio have more severe
illness [12,13,16,17]. The capability of RV to induce Th2-
type cytokines (IL-4 and IL-5) has been less pronounced
in previous in vitro studies compared to IFN-gamma
responses as also supported by in vivo data [14,29].
Although it is possible that RV-infection worsens Th2-type
inflammation, the presence of Th2-type cytokines more
likely may reflect a chronic inflammatory state of lower
airways, which may increase susceptibility to RV infec-
tions [17,30]. Furthermore, Th2-type cytokines could
counteract Th1-type cytokines, and thereby, may increase
susceptibility to more severe RV-infections [12,15,17,25].
In agreement, the RV affected children had markedly
higher systemic levels of IL-5 and IL-13 than those
affected by RSV in our study, but this difference appeared
to be linked to atopy. The difference in Th2-type cytokines
was not so striking when RV-group was compared to
atopy/age-matched controls and seen only in IL-5 in the
acute phase and not seen at all in the convalescence phase.
These findings fit in the previously reported close associa-
tion between RV infections and atopic characteristics
[5,14]. Interestingly, the IL-13 response was markedly
higher in RV affected children than in those affected by
RSV in our study. IL-13 is known to play critical role in air-
way hyperreactivity and amplifying allergic inflammation
in asthma [17,26]. It should be noted that certain poly-
morphism, such as IL-4 590T and IL-4Ralpha R551 alle-
les, could be linked to more sereve bronchiolitis and the
IL-13 Gln allele may identify children at risk for persistent
wheezing as shown in RSV affected children [18,20].
Of the studied cytokines, IL-10 tends to have immunoreg-
ulatory properties and its generation is usually associated
with resolution of the inflammatory process [31]. Moreo-
ver, it is also associated with airway hyperreactivity, and
blood CD 4+ IL-10 level has inversely correlated with nasal
RV load [17,26]. Our findings on IL-10 are very similar to
the reports by Grissell et al. (2005) [32]. They studied
cytokine gene expression by quantitative PCR in the
induced sputum of mainly adult subjects (>7-year-old)
with virus induced acute asthma (64% of subjects had
RV). They found that IL-10 mRNA was increased in virus-
infected acute asthma and reduced on recovery phase. We
further showed that IL-10 was elevated in both virus
groups in the acute phase when compared to the convales-
cence phase and also when RV-group was compared to the
control group. The finding that IL-10 level was greater in
the RV-group than in the RSV-group in the convalescent
phase is probably linked to predisposition (atopy) since
no difference was found in this time-point when com-
pared to the control group. The increased IL-10 level in
acute viral infection could mean that IL-10 is a causative
mediator in virus provoked exacerbation (triggered by
IFN-gamma), and that the generation of IL-10 is a
response to a greater degree of pre-existing airway inflam-
mation in individuals predisposed to virus, especially to
RV, induced exacerbations, and serve to promote toler-
ance [17,33]. Whether IL-10 levels reflect Treg activity, it is
intriguing to speculate that the patients with decreased IL-
10 responses (thereby defective down regulation of Th1
and Th2  responses) could have greater inflammatory
response to viral infections (e.g. to >150 circulating RV
strains) [9,10] and thereby increased risk for recurrent
wheezing. In agreement, a recent study reported lower IL-
10 levels in stimulated cord blood of children who were
hospitalized for RSV infection before 6 months of age
compared to those who were treated as outpatients [34].
Interestingly, children homozygous for the IL-10 -592C, -
592A or IL-10 -1082A allele have had a high risk of severe
bronchiolitis [19,21].
It can be debated whether rhinovirus PCR positivity can
be considered as an indication of a real infection [3].
Recent data, however, suggests that it can. First, RV-PCR
positive respiratory findings have been linked to the sever-
ity of respiratory illness [1,35]. Second, although virus
replication lasts usually longer than clinical illness, PCR
positivity has been rather short-lasting (usually <2 weeks)
in RV-genotype specific analysis [35]. Third, the current
data adds that RV PCR positivity is also linked to systemic
immune responses.
The strengths of the study include detailed viral diagnos-
tics, careful characterization of atopic characteristics, nat-
ural illness and in vivo samples of normal population
although our hospitalized cohort probably represents the
most severe end of illness. The group of corticosteroid
naive children in the follow-up was not biased since all
the study children were initially randomized to pred-
nisolone or placebo treatments. The use of non-steroidal
anti-inflammatory drugs or acetaminophen was not
recorded, but their effect on cytokine levels is considered
negligible when recommended doses are used [36,37] As
a limitation, newly recognized type-C and type-D RVs
may have evaded our PCR [9,10]. Furthermore, systemic
cytokine responses may not reflect the responses in the
airways [38].Respiratory Research 2009, 10:85 http://respiratory-research.com/content/10/1/85
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The study demonstrates the difficulty of comparing RSV-
and RV affected young wheezing children since RV infec-
tion is closely associated with atopy, whereas RSV is not,
and RV typically affects slightly older children than RSV
infection (5, 22). Almost 2 year recruitment period in a
relatively large university hospital resulted only 2 RV cases
of all eligible cases to match RSV cases (1st episode, non-
topic and blood eosinophil count <0.4 × 109/L). On the
other hand, RSV cases are difficult to match to RV cases
due to rare association to atopy (only one case in our
study).
Conclusion
The young wheezing children infected by RV and RSV dif-
fer significantly in terms of age, atopic characteristics, or
systemic cytokine responses. Our results support a
hypothesis that rhinovirus is likely to trigger early wheez-
ing in children with a predisposition, who are old enough
to develop a distinct atopy-related asthma-prone pheno-
type [5]. The elevated levels of IFN-gamma, IL-13 and IL-
10 (pre-existing or virus-induced) in RV-affected children
underline the importance of these cytokines in the early
pathogenesis of asthma and the detection of RV as an
important, maybe not a risk factor, but a revealing factor
for a high risk phenotype [5-8,17,26].
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